BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36108578)

  • 1. Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study.
    Kaumanns A; König D; Hojski A; Cattaneo M; Chirindel A; Wiese M; Tamm M; Lardinois D; Rothschild SI
    Lung Cancer; 2022 Nov; 173():14-20. PubMed ID: 36108578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients.
    Toba H; Kawakita N; Takashima M; Matsumoto D; Takizawa H; Otsuka H; Tangoku A
    Gen Thorac Cardiovasc Surg; 2021 Feb; 69(2):311-317. PubMed ID: 32909168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
    Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
    Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
    Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
    Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistency and prognostic value of preoperative staging and postoperative pathological staging using
    Kajiyama A; Ito K; Watanabe H; Mizumura S; Watanabe SI; Yatabe Y; Gomi T; Kusumoto M
    Ann Nucl Med; 2022 Dec; 36(12):1059-1072. PubMed ID: 36264439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
    Gauger J; Patz EF; Coleman RE; Herndon JE
    J Thorac Oncol; 2007 Jun; 2(6):499-505. PubMed ID: 17545844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can surgical adhesives may cause false positivity in follow-up positron emission tomography after lung cancer resection?
    Doğan R; Uysal S; Kumbasar U; Köksal D; Ancın B; Tuncel M
    Tuberk Toraks; 2021 Mar; 69(1):59-64. PubMed ID: 33853306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
    Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA
    Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
    Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
    Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
    Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art.
    Castello A; Rossi S; Lopci E
    Curr Radiopharm; 2020; 13(3):228-237. PubMed ID: 31886757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of different
    Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
    Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.